# Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

> **NCT06395103** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 90 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- Diffuse Large B-cell Lymphoma
- Burkitt Lymphoma
- Neuroblastoma
- Ewing Sarcoma

## Interventions

- **BIOLOGICAL:** Zilovertamab vedotin

## Key facts

- **NCT ID:** NCT06395103
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-16
- **Primary completion:** 2029-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06395103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06395103, "Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06395103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*